View Older Stories View More Recent Stories

Jul 3, 2024 11:16AM CNS Pharmaceuticals (CNSP) Prices 1.425M Share Offering at $1.39/sh
Jul 3, 2024 11:10AM CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Jun 26, 2024 08:03AM CNS Pharmaceuticals (CNSP) Prices Share and Warrant Offering at $2.45/sh
Jun 26, 2024 08:00AM CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Jun 14, 2024 03:13PM CNS Pharmaceuticals (CNSP) Prices Registered Direct Offering and Concurrent Private Placement
Jun 14, 2024 03:11PM CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Jun 3, 2024 08:08AM CNS Pharmaceuticals (CNSP) Announces 1-for-50 Reverse Stock Split
Jun 3, 2024 08:05AM CNS Pharmaceuticals Announces Reverse Stock Split
Jun 3, 2024 08:05AM CNS Pharmaceuticals Announces Reverse Stock Split
Apr 23, 2024 09:00AM CNS Pharmaceuticals to Present at the LSX World Congress 2024
Apr 22, 2024 12:00AM CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
Apr 1, 2024 04:26PM CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
Apr 1, 2024 09:05AM CNS Pharmaceuticals to Present at Two Investor Conferences in April
Jan 30, 2024 05:48AM CNS Pharmaceuticals (CNSP) Prices 13.33M Share Offering at $0.30/sh
Jan 29, 2024 09:00PM CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
Jan 18, 2024 08:46AM CNS Pharmaceuticals (CNSP) Appoints Amy Mahery to its Board
Jan 18, 2024 08:45AM Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
Jan 17, 2024 08:45AM CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Dec 18, 2023 08:40AM CNS Pharmaceuticals (CNSP) Announces Successful Interim Analysis of Efficacy and Safety Data in Study of Berubicin
Dec 18, 2023 08:35AM CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
Nov 22, 2023 09:08AM CNS Pharmaceuticals (CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Nov 22, 2023 09:05AM CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Nov 15, 2023 08:00AM CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
Oct 19, 2023 09:05AM CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
Oct 11, 2023 08:45AM CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Da
Sep 7, 2023 08:45AM CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
Sep 5, 2023 08:45AM CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 08:39AM CNS Pharmaceuticals (CNSP) Presents Updated Results from On-Going Study of Berubicin
Aug 14, 2023 08:35AM CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Lin
Aug 14, 2023 07:35AM CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
Aug 3, 2023 08:15AM CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
Aug 3, 2023 08:04AM CNS Pharmaceuticals (CNSP) Provides Clinical Trial Update for Ongoing Study with Berubicin
Aug 3, 2023 08:00AM CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Jul 27, 2023 09:05AM CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
Jul 5, 2023 08:45AM CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series
Jun 14, 2023 09:05AM CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
May 15, 2023 08:35AM CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 08:48AM CNS Pharmaceuticals (CNSP) Appoints Bettina M. Cockroft to its Board
May 8, 2023 08:45AM Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
May 3, 2023 08:47AM CNS Pharmaceuticals (CNSP) Retains Shareholder Intelligence Services to Investigate Potential Naked Short Selling
May 3, 2023 08:45AM CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC
Apr 27, 2023 08:45AM CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
Apr 10, 2023 08:45AM Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Apr 6, 2023 09:05AM CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Apr 3, 2023 08:05AM CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 29, 2023 09:05AM CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event
Mar 13, 2023 07:05AM CNS Pharmaceuticals (CNSP) Has No Exposure to Silicon Valley Bank Issues
Mar 13, 2023 07:05AM CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues
Mar 9, 2023 09:05AM CNS Pharmaceuticals (CNSP) Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Mar 9, 2023 09:05AM CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
View More Recent Stories View Older Stories